A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets

Michael J. Wasko, Kendy A. Pellegrene, Jeffry D. Madura, Christopher K. Surratt
2015 Frontiers in Neurology  
Citation: Wasko MJ, Pellegrene KA, Madura JD and Surratt CK (2015) A role for fragment-based drug design in developing novel lead compounds for central nervous system targets. Hundreds of millions of U.S. dollars are invested in the research and development of a single drug. Lead compound development is an area ripe for new design strategies. Therapeutic lead candidates have been traditionally found using high-throughput in vitro pharmacological screening, a costly method for assaying thousands
more » ... of compounds. This approach has recently been augmented by virtual screening (VS), which employs computer models of the target protein to narrow the search for possible leads. A variant of VS is fragment-based drug design (FBDD), an emerging in silico lead discovery method that introduces low-molecular weight fragments, rather than intact compounds, into the binding pocket of the receptor model. These fragments serve as starting points for "growing" the lead candidate. Current efforts in virtual FBDD within central nervous system (CNS) targets are reviewed, as is a recent rule-based optimization strategy in which new molecules are generated within a 3D receptor-binding pocket using the fragment as a scaffold. This process not only places special emphasis on creating synthesizable molecules but also exposes computational questions worth addressing. Fragment-based methods provide a viable, relatively low-cost alternative for therapeutic lead discovery and optimization that can be applied to CNS targets to augment current design strategies.
doi:10.3389/fneur.2015.00197 pmid:26441817 pmcid:PMC4566055 fatcat:5sgh6okhgbgpfpdavsdw42hjuu